Sunday, February 15, 2026 2/15/2026

Prospective Development of a Multimodal Biomaker Platform for Predictive Risk Stratification of Cardiac Disease in Duchenne Muscular Dystrophy

Award Number: R01FD006649
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2019
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Prospective Development of a Multimodal Biomaker Platform for Predictive Risk Stratification of Cardiac Disease in Duchenne Muscular Dystrophy - PROJECT SUMMARY/ABSTRACT Duchenne muscular dystrophy (DMD) is a rare and devastating disease with no cure affecting 1 in 4700 male births. DMD results in loss of ambulation, respiratory failure, cardiomyopathy (CM), and premature death. CM is the leading cause of death in DMD, but CM progression is variable. Currently, there are no genetic, blood, or imaging biomarkers that can predict high- or low-risk cardiovascular phenotype. More importantly, there are no established cardiac outcome measures. Novel, targeted therapeutics are necessary to treat DMD CM, but this knowledge gap makes clinical trials challenging. A better understanding of CM disease progression is critical to improve clinical trial efficiency. To address these obstacles, we propose a rigorous, prospective, serial evaluation in the largest cohort of DMD patients with complete cardiovascular phenotyping. This study will assess serum and imaging markers of fibrosis as surrogate biomarkers of disease progression and ultimately mortality. It will leverage the DMD Cardiac Consortium (created as part of the PIs R56), which has standardized cardiac MRI and skeletal muscle protocols for the assessment of DMD progression. We will combine this prospective evaluation with a comprehensive assessment of genetic polymorphisms performed using DNA collected from the largest DMD registry. The central hypothesis of this proposal is that imaging and blood biomarkers detect subclinical myocardial fibrosis with potential for use as surrogate biomarkers of CM in DMD. We further hypothesize genotyping in a large sample size of DMD patients can determine the impact of genetic polymorphisms on DMD CM progression. Aim 1 will collect DNA using the largest DMD registry to discover genetic variants that determine DMD CM severity. Aim 2 will identify serum biomarkers that characterize DMD CM disease severity. Aim 3 will define the longitudinal progression of DMD CM in the current era and determine serum and imaging measures of myocardial fibrosis that herald a subsequent change in cardiac function. The proposed studies will include four of the larger cardiac muscular dystrophy centers in the country and will create the largest cohort of DMD patients with rigorous cardiovascular phenotyping. The consortium has been constructed to allow additional sites to join in order to foster the larger collaborative efforts necessary to achieve meaningful results in this rare disease. This project directly addresses the goals of the funding mechanism to characterize the natural history of rare diseases, identify genotype and phenotype subpopulations, and develop clinical outcome measures. These results will have clinical relevance for other similar diseases, including Becker muscular dystrophy and female mutation carriers. The innovation of this grant is the integration of genetic polymorphisms with imaging and blood biomarkers to identify surrogate biomarkers of cardiovascular disease. The ability to readily test novel and targeted therapies is crucial for lengthening and improving the quality of life in boys and men with DMD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	000	4	2/6/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $675,698 )
2024	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	000	4	3/18/2024	NON-COMPETING CONTINUATION	$675,698
														Subtotal = $675,698

Issue Date FY: 2023 ( Subtotal = $604,256 )
2023	2023	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	000	3	2/24/2023	NON-COMPETING CONTINUATION	$604,256
														Subtotal = $604,256

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	000	2	8/23/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $577,922 )
2021	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	003	2	7/29/2021	NON-COMPETING CONTINUATION	$577,922
2021	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	004	2	8/12/2021	NON-COMPETING CONTINUATION	$0
2021	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	000	1	12/21/2020	NEW	$0
2021	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	001	1	1/25/2021	NEW	$0
2021	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	002	1	7/29/2021	NEW	$0
														Subtotal = $577,922

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	000	1	9/4/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $604,403 )
2019	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Food and Drug Administration Research	000	1	9/11/2019	NEW	$604,403
														Subtotal = $604,403

Grand Total All Awards = $2,462,279

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Prospective Development of a Multimodal Biomaker Platform for Predictive Risk Stratification of Cardiac Disease in Duchenne Muscular Dystrophy

Award Number: R01FD006649

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2019

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer